Positive new real-world data on Tresiba switching

Findings from the real-world study, EU-TREAT (EUropean TREsiba AudiT), were presented on Saturday at the American Diabetes Association’s 77th Scientific Sessions (ADA) in San Diego, USA.

The study showed that people with type 1 diabetes and type 2 diabetes experienced a significant reduction in HbA1c (-0.2% for type 1 diabetes and -0.5% for type 2 diabetes) six months after switching to Tresiba (insulin degludec) from another basal insulin, primarily insulin glargine U100 and insulin detemir, in a real-world setting. These results were sustained at 12 months, commented Danish diabetes care giant Novo Nordisk (NOV: N), whose Tresiba generated sales of 1.49 billion kroner ($226 million) in the first quarter of this year.

Rates of overall hypoglycemia were also significantly lower at six months after switching to Tresiba. In people with type 1 diabetes, the rate of severe hypoglycemia was reduced by 85% and by 92% in people with type 2 diabetes. Hypoglycemia outcomes at 12 months were in line with these results.